Toggle Health Problems and D

Drug–Vitamin D Interactions, A Systematic Review – Jan 2013

Nutr Clin Pract January 10, 2013 0884533612467824
Kim Robien, PhD, RD, CSO 1
Sarah J. Oppeneer, MS 2
Julia A. Kelly, MS, MLIS 3
Jill M. Hamilton-Reeves, PhD, RD 4
1 Department of Epidemiology and Biostatistics, George Washington University School of Public Health and Health Services, Washington, DC
2 Division of Epidemiology and Community Health, University of Minnesota, Minneapolis
3 University Libraries, University of Minnesota, Minneapolis
4 University of Kansas Medical Center, School of Health Professions, Department of Dietetics & Nutrition, Kansas City, Kansas
Kim Robien, PhD, RD, CSO, Associate Professor, Department of Epidemiology and Biostatistics, George Washington University School of Public Health and Health Services, 2100-W Pennsylvania Ave NW, 8th Floor, Washington, DC, 20037, USA. Email: krobien at gwu.edu.

Extensive media coverage of the potential health benefits of vitamin D supplementation has translated into substantial increases in supplement sales over recent years. Yet, the potential for drug–vitamin D interactions is rarely considered. This systematic review of the literature was conducted to evaluate the extent to which drugs affect vitamin D status or supplementation alters drug effectiveness or toxicity in humans. Electronic databases were used to identify eligible peer-reviewed studies published through September 1, 2010. Study characteristics and findings were abstracted, and quality was assessed for each study.
A total of 109 unique reports met the inclusion criteria.
The majority of eligible studies were classified as class

  • C (nonrandomized trials, case-control studies, or time series) or
  • D (cross-sectional, trend, case report/series, or before-and-after studies).
      Only 2 class C and 3 class D studies were of positive quality.

Insufficient evidence was available to determine whether

  • lipase inhibitors,
  • antimicrobial agents,
  • antiepileptic drugs,
  • highly active antiretroviral agents, or
  • H2 receptor antagonists
      alter serum 25(OH)D concentrations.


  • Atorvastatin appears to increase 25(OH)D concentrations, whereas
  • concurrent vitamin D supplementation decreases concentrations of atorvastatin.
  • Use of thiazide diuretics in combination with calcium and vitamin D supplements
      may cause hypercalcemia in the elderly or those with compromised renal function or hyperparathyroidism.

Larger studies with stronger study designs are needed to clarify potential drug–vitamin D interactions,
especially for drugs metabolized by cytochrome P450 3A4 (CYP3A4).

Healthcare providers should be aware of the potential for drug–vitamin D interactions.

Partial PDF Table of Contents

 Download the PDF from VitaminDWiki

See also VitaminDWiki

Attached files

ID Name Comment Uploaded Size Downloads
10831 Interactions ToC.jpg admin 11 Nov, 2018 19:54 23.29 Kb 669
10830 Intractions.jpg admin 11 Nov, 2018 19:49 70.35 Kb 992
10829 Drug-vitamin D interactions.pdf admin 11 Nov, 2018 19:45 914.97 Kb 552
See any problem with this page? Report it (WORKS NOV 2021)